Neurobiological Technologies, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurobiological Technologies, Inc.
Diversification Gains Momentum As Companies Look To Derisk China
Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
BMS Fast Tracks CAR-T Manufacturing With Cellares Deal
In a partnership worth $380m, BMS has reserved clinical and commercial capacity with Cellares, a company whose $255m series C round it participated in last year.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice